NCT05382169

Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders

Prevalence of Mast Cell Activation Syndrome in Patients With Ehlers Danlos Hypermobile Syndrome With Digestive Disorders

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Lille Catholic University · Academic / Other
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.

Conditions

• Ehlers Danlos Hypermobile Syndrome

Interventions

Type	Name	Description
OTHER	Determine the presence of mast cell activation syndrome	Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) : * At least two clinical signs compatible with MAS before the first consultation (V1) * Improvement of symptoms on antihistamines within 2 months of initiation of treatment * Significant increase in tryptase during crisis Mast cell activation syndrome will be possible if : * At least two clinical signs consistent with MAS before the first consultation (V1) * Improvement of symptoms with antihistamines within 2 months of initiation of treatment * No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely.

Timeline

• Start date: 2022-09-28
• Primary completion: 2025-01-01
• Completion: 2026-03-01
• First posted: 2022-05-19
• Last updated: 2023-01-11

Locations

1 site across 1 country: France